convalescent plasma treatment - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.80 [0.46, 1.41]< 10%2 studies (2/-)77.8 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical improvement 1.04 [0.61, 1.78]> 151%2 studies (2/-)55.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
ventilation 0.67 [0.22, 2.02]< 10%1 study (1/-)76.1 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.40 [0.78, 2.51]< 10%1 study (1/-)13.0 %lownot evaluable highimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.